Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...1819202122232425262728...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Cyramza (ramucirumab) / Eli Lilly
    Trial completion date, Trial primary completion date:  TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) -  Jan 25, 2021   
    P2,  N=25, Recruiting, 
    This study provides clear evidence to evaluate the effectiveness and safety of trifluridine/tipiracil for patients with highly pretreated metastatic gastric cancer, and the findings will also be published in a peer-reviewed journal. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2021 --> Jan 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TTY Biopharm, Avastin (bevacizumab) / Roche
    P1 data, Journal:  Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. (Pubmed Central) -  Jan 23, 2021   
    Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2021 --> Jan 2022 Tolerability and activity observed in this phase I trial support further investigation of the FTD/TPI-irinotecan-bevacizumab combination in previously treated mCRC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Questionnaire Survey of Third-Line Chemotherapy for Gastric Cancer in Yamaguchi Prefecture (Pubmed Central) -  Jan 22, 2021   
    Nivolumab was used as the first-choice in more than 80% of the regimens for gastric cancer third-line chemotherapy in Yamaguchi prefecture. There was a difference in consciousness among doctors regarding the timing of switching from second- line to third-line chemotherapy and the timing of switching from nivolumab to fourth-line therapy.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Journal:  Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy (Pubmed Central) -  Jan 22, 2021   
    Here, we successfully treated 38 months survival case after recurrences following radical gastrectomy for advanced adenocarcinoma of esophago-gastric junction using historical recommended chemotherapy regimens and trifluridine/tipiracil as a fifth-line chemotherapy. Trifluridine/tipiracil therapy contributed to effective and safety treatment even in late-line chemotherapy for recurrent gastric cancer.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Retrospective data, Journal, Adverse events:  Effect on Prognosis of Immune-Related Adverse Events after Nivolumab Treatment in Gastric Cancer (Pubmed Central) -  Jan 22, 2021   
    Trifluridine/tipiracil therapy contributed to effective and safety treatment even in late-line chemotherapy for recurrent gastric cancer. Long-term efficacy is expected with nivolumab, but it may be necessary to recognize that the onset of serious irAEs might make subsequent treatment difficult.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Ibrance (palbociclib) / Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Trial completion date, Trial primary completion date, Metastases:  ACCRU-GI-1618: Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer (clinicaltrials.gov) -  Jan 22, 2021   
    P2,  N=112, Recruiting, 
    In conclusion, the TAS-102 plus Bev therapy may be a useful option for the late-line treatment of unresectable advanced recurrent colorectal cancer. Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2020 --> Dec 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment closed, Combination therapy, Metastases:  TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  Jan 20, 2021   
    P1,  N=20, Active, not recruiting, 
    Trial primary completion date: Jan 2021 --> Jan 2023 Recruiting --> Active, not recruiting
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial primary completion date, Combination therapy, Metastases:  TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  Jan 8, 2021   
    P1,  N=20, Recruiting, 
    CLINICALTRIALS. Trial primary completion date: Dec 2020 --> May 2021
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Trial primary completion date, Combination therapy:  Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE (clinicaltrials.gov) -  Jan 5, 2021   
    P1,  N=57, Recruiting, 
    TT-B treatment showed promising clinical activity in untreated patients with unresectable mCRC ineligible for intensive therapy, with an acceptable safety profile and no clinically relevant changes in QoL. Trial primary completion date: Dec 2020 --> Mar 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) (clinicaltrials.gov) -  Dec 17, 2020   
    P1,  N=18, Recruiting, 
    Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (clinicaltrials.gov) -  Dec 16, 2020   
    P1,  N=48, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
    Journal:  TAS-102 has a tumoricidal activity in multiple myeloma. (Pubmed Central) -  Dec 10, 2020   
    TAS-102 has shown its efficacies in the drug-resistant myeloma cells, and the combination of TAS-102 and bortezomib has a synergistic anti-myeloma activity. Our preclinical studies indicate that TAS-102 is a potential novel agent for myeloma therapy.
  • ||||||||||  Elunate (fruquintinib) - Chi / Med
    [VIRTUAL] FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC). () -  Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_405;    
    P3
    Current standard of care (SOC) after pts progress on trifluridine/tipiracil (TAS-102) or regorafenib is re-challenge with previous systemic treatments, enrollment in a clinical trial, or best supportive care (BSC)...Fruquintinib is approved in China to treat pts with mCRC who received or are intolerant to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, if RAS wild type, anti-epidermal growth factor receptor (EGFR) therapy...If enrichment of post-regorafenib pts occurs, enrollment to that strata will be capped at approximately 262. FRESCO-2 will be activated in the US, EU, and Japan; global enrollment is anticipated over 13 mo.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    [VIRTUAL] Continuing education curriculums and outcomes on progressive metastatic colorectal cancer treatment. () -  Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_122;    
    This series of online, expert-led, CME-certified educational activities resulted in significant improvement in knowledge, competence, confidence, and performance among learners regarding the management of patients with progressive metastatic colorectal cancer over time. These results demonstrate the effectiveness of on-demand education as new data emerge and indications expand to reinforce existing knowledge, close persistent gaps, and increase confidence in managing these patients.